RAS相关的C3肉毒素底物1在胃癌中高表达并促进胃癌细胞增殖、迁移和侵袭被引量：1

Overexpression of RAS related C3 botulinum tox substrate 1 in gastric cancer and promotion of gastric cancer cell proliferation,migration and invasion

原文传递

导出

摘要目的:探究RAS相关的C3肉毒素底物1(RAC1)在胃癌中的表达及其与临床病理学特征的相关性,并观察RAC1对胃癌细胞的增殖、迁移等生物学特性的影响。方法:使用免疫组织化学染色方法研究RAC1在胃癌中的表达情况。分别使用χ2检验及Kaplan-Meier生存分析的统计学方法分析RAC1的表达与胃癌临床病理学的特征及预后的相关性。并探究高表达RAC1在体外实验中对胃癌细胞生长、迁移、侵袭的影响。结果:RAC1在胃癌组织中高表达,且不同分化程度、有无局部侵袭、淋巴结转移和不同Lauren’s分型间均有差异(均P<0.05)。RAC1高表达预示了胃癌患者的不良预后。在胃癌细胞中诱导RAC1高表达后发现其在体外促进胃癌细胞的生长、迁移及侵袭(均P<0.05)。使用特异性抑制剂抑制RAC1表达后发现,胃癌细胞生长、迁移及侵袭的生物学功能也受到相应的抑制(均P<0.05)。结论 :RAC1与胃癌的侵袭性相关且是预后不良的指标。体外实验结果也进一步证实了RAC1高表达与胃癌细胞的侵袭性相关,鉴于其在胃癌生长及进展中所起的重要作用,RAC1可作为胃癌治疗的潜在靶点。 Objective To investigate the expression and clinical significance of RAS related C3 botulinum tox substrate1（RAC1） and the role of RAC1 in gastric cancer tumorigenesis and metastasis. Methods The expression of RAC1 in human gastric cancer was detected by immunohistochemistry. The correlation of RAC1 expression with clinicopathological characteristics and survival of patients was analyzed by Pearson＇s χ2and Kaplan-Meier analyses,respectively. RAC1 overexpression cell model was used to examine in vitro effects of RAC1 on cell growth,migration,and invasion. Results RAC1 was highly expressed in gastric cancer tissue,and was different in relation with differentiation,local invasion,lymph node metastasis,and Lauren＇s classification. RAC1 overexpression in gastric cancer predicted a shorter survival. In vitro study showed that in gastric cancer cells,overexpression of RAC1 induced would promote cell proliferation,migration and invasion（all P 0.05）,and inhibition of RAC1 by specific inhibitor would abrogate these effects（all P 0.05）. Conclusions These findings demonstrated that RAC1 was positively correlated with the aggression of gastric cancer and was a factor for poor prognosis. In addition,experimental cell models supported the role of RAC1 in promotion of gastric cancer cell growth,migration and invasion. Given its pivotal role in tumorigenesis and progression,RAC1 could be served as a promising therapeutic target for gastric cancer.

作者冯晓静余韵丁秋兰卢莹

机构地区上海交通大学医学院病理生理学教研室细胞分化与凋亡教育部重点实验室上海交通大学医学院附属瑞金医院检验科

出处《内科理论与实践》 2015年第5期353-358,共6页 Journal of Internal Medicine Concepts & Practice

关键词 RAC1 胃癌转移肿瘤形成预后 RAC1 Gastric cancer Metastasis Tumorigenesis Prognosis

分类号 R735.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献14

1陈凛,李涛.进展期胃癌外科治疗的相关问题与思考[J].中华胃肠外科杂志,2007,10(5):413-415. 被引量：21
2Zhao P, Dai M, Chen W, et al. Cancer trends in China[J]. Jpn J Clin Oncol, 2010, 40(4): 281-285.
3Li ZX, Kaminishi M. A comparison of gastric cancer be-tween Japan and China[J]. Gastric Cancer, 2009, 12(1): 52-53.
4Wu AW, Ji JF, Yang H, et al. Long-term outcome of a large series of gastric cancer patients in China[J]. Chin J Cancer Res, 2010, 22(3): 167-175.
5Halt WN, Hambley TW. Targeted cancer therapeutics[J]. Cancer Res, 2009, 69(4): 1263-1267.
6Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive ad- vanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled tri- al[l]. Lancet, 2010, 376(9742): 687-697.
7Oleinik NV, Helke KL, Kistner-Griffin E, et al. Rho GTPases RhoA and RAC1 mediate effects of dietary fo- late on metastatic potential of A549 cancer ceils through the control of cofilin phosphorylation[J]. J Biol Chem, 2014, 289(38): 26383-26394.
8Leve F, Morgado-Diaz JA. Rho GTPase signaling in the development of colorectal cancer[J]. J Cell Biochem, 2012, 113(8): 2549-2559.
9Bid HK, Roberts RD, Manehanda PK, et al. RACI: an e- merging therapeutic option for targeting cancer angiogen- esis and metastasis[J]. Mol Cancer Ther, 2013, 12(10): 1925-1934.
10Wang X, Deng Y, Mao Z, et al. CCN1 promotes tumori- genicity through RACI/Akt/NF-KB signaling pathway in pancreatic cancer[J]. Tumour Biol, 2012, 33(5): 1745- 1758.

二级参考文献13

1Archie V, Kauh J, Dennie V, et al. Gastric cancer:standards for the 21st century. Crit Rev Oncol Hematol, 2006,57: 123- 131.
2Tsujinaka T, Sasako M, Yamto S, et al. Influence of overweight on surgical complications for gastric cancer:results from a randomized control trial companing DE and extended pana-aortic D3 lymphadenectomy (JCOG 9501). Ann Surg Oncol, 2007,14 : 355-361.
3Uyama I, Sakurai Y, Komori Y, et al. The advances of laparoscopic treatment for gastric cancer. Gan To Kagaku Ryoho, 2007,34 : 21-24.
4Huscher CG, Mingoli A, Sgarzini G, et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer:fiveyear results of a randomized prospective trial. Ann Surg, 2005, 241 : 232-237.
5Varela JE, Hiyashi M, Nguyen T, et al. Comparison of laparoscopic and open gastrectomy for gastric cancer. Am J Surg, 2006,192 : 837-842.
6Kitano S, Shiraishi N. Current status of laparoscopic gastrectomy for gastric cancer in Japan. Surg Endosc, 2004, 18: 182-185.
7Hofler H, Langer R, Ott K, et al. Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Adv Exp Med Biol, 2006,587: 115-120.
8D'Ugo D, Persiani R, Rausei S, et al. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol, 2006,32: 1105-1109.
9Katayama K, Hirono Y, Murakami, et al. Intraperitoneal chemotherapy in gastric cancer patients with peritoneal dissemination. Gan To Kagaku Ryoho, 2005,32 : 1404- 1409.
10Fujimoto S, Takahashi M, Muton T, et al. Sueccessful intraperitioncal hyperthenic ehemopefusion for the prevention of postoperative peritoneal reucrrence in patients with advanced gastric cancer. Cancer, 1999,85:529-534.